News | January 31, 2026
Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The collaboration will center on expanding access to Eastman’s Esmeri technology
The partnership initially will focus on cardiovascular and kidney diseases
This marks the second indication for which gumokimab has gained NDA review acceptance
Subscribe To Our Newsletter & Stay Updated
